By Doug Macron

Just six months after transforming itself into a drug developer focused on both RNAi and cancer immunotherapies, RXi Pharmaceuticals said this week that it will spin out its activities with the gene-silencing technology into a new publicly traded company.

The new RNAi firm will retain the RXi name, while the other half of the company's operations, which will focus solely on the immunotherapy activities, will be conducted as Galena Biopharma.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits sequencing newborns is underway.